Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARAV NASDAQ:CYAD NASDAQ:MBIO NASDAQ:NCNA OTCMKTS:NWPHF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARAVAravive$0.04$0.04$0.04▼$2.46$2.95M2.19N/AN/ACYADCelyad$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsMBIOMustang Bio$2.65-1.1%$1.33$0.89▼$24.00$11.61M2.161.60 million shs1.44 million shsNCNANuCana$0.05-15.9%$0.11$0.03▼$10.79$305K1.4248.50 million shs220.74 million shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARAVAravive0.00%0.00%0.00%0.00%0.00%CYADCelyad0.00%0.00%0.00%0.00%0.00%MBIOMustang Bio-13.83%+120.58%+111.02%+92.81%-87.88%NCNANuCana-1.00%+8.35%-58.40%-92.04%-98.03%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%-22.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARAVAraviveN/AN/AN/AN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio1.2284 of 5 stars0.05.00.00.02.80.00.6NCNANuCana2.5812 of 5 stars3.32.00.00.01.12.51.3NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARAVAravive 0.00N/AN/AN/ACYADCelyad 0.00N/AN/AN/AMBIOMustang Bio 0.00N/AN/AN/ANCNANuCana 2.50Moderate Buy$25.0049,700.80% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARAVAravive$6.99M0.42N/AN/AN/A∞CYADCelyad$200K79.56N/AN/A$0.02 per share30.00MBIOMustang BioN/AN/AN/AN/A($2.11) per shareN/ANCNANuCanaN/AN/AN/AN/A$1.34 per shareN/ANWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARAVAravive-$76.32MN/A0.00∞N/AN/AN/AN/AN/ACYADCelyad-$6.30MN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$15.75M-$78.00N/AN/AN/AN/AN/A-80.79%8/12/2025 (Estimated)NCNANuCana-$24.28M-$7.02N/AN/AN/AN/A-319.85%-88.55%8/13/2025 (Estimated)NWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/ALatest NWPHF, MBIO, NCNA, ARAV, and CYAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/2/2025Q1 2025NCNANuCana-$0.0129-$0.63-$0.6171-$0.63N/AN/A5/14/2025Q1 2025MBIOMustang BioN/A-$0.05N/A-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARAVAraviveN/AN/AN/AN/AN/ACYADCelyadN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ANCNANuCanaN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARAVAraviveN/AN/AN/ACYADCelyad1.492.292.14MBIOMustang BioN/A1.341.34NCNANuCanaN/A1.251.25NWPHFNewron PharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARAVAravive35.80%CYADCelyadN/AMBIOMustang Bio9.95%NCNANuCana44.00%NWPHFNewron PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipARAVAravive60.40%CYADCelyad0.94%MBIOMustang Bio0.21%NCNANuCana31.20%NWPHFNewron PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARAVAravive2073.56 million29.13 millionNo DataCYADCelyad9526.52 million26.28 millionNot OptionableMBIOMustang Bio1004.38 million4.37 millionNot OptionableNCNANuCana306.08 million4.18 millionNot OptionableNWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableNWPHF, MBIO, NCNA, ARAV, and CYAD HeadlinesRecent News About These CompaniesEdison Issues Report on Newron Pharmaceuticals (NWRN)July 9 at 7:23 AM | newsfilecorp.comNNewron Pharmaceuticals S.p.A. Just Missed EPS By 53%: Here's What Analysts Think Will Happen NextApril 5, 2025 | finance.yahoo.comEQS-News: Newron presents 2024 financial results and provides 2025 outlookApril 1, 2025 | markets.businessinsider.comNewron Pharmaceuticals S.p.A.: Newron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finanznachrichten.deNewron Presents 2024 Financial Results and Provides 2025 OutlookApril 1, 2025 | finance.yahoo.comNewron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | uk.finance.yahoo.comEQS-News: Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent ChairmanMarch 24, 2025 | markets.businessinsider.comThose who invested in Newron Pharmaceuticals (VTX:NWRN) three years ago are up 548%March 17, 2025 | finance.yahoo.comNewron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH ConferenceMarch 11, 2025 | businesswire.comNewron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South KoreaJanuary 11, 2025 | pharmabiz.comPNewron and Myung In Pharm announce license agreement for schizophrenia therapy in South KoreaJanuary 10, 2025 | financialexpress.comFNewron and Myung In Pharm sign agreement for evenamide developmentJanuary 10, 2025 | pharmaceutical-technology.comPEQS-News: Newron and Myung In Pharm announce license agreement for evenamide in South KoreaJanuary 9, 2025 | markets.businessinsider.comNewron out-licenses evenamide in South KoreaJanuary 9, 2025 | thepharmaletter.comTNewron and Myung In Pharm Announce License Agreement for evenamide in South KoreaJanuary 9, 2025 | finance.yahoo.comEvenamide by Newron Pharmaceuticals for Schizophrenia: Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPNewron stock soars on €117M EA Pharma deal for schizophrenia drugDecember 17, 2024 | bioworld.comBNewron out-licenses evenamide to Eisai unit EA PharmaDecember 13, 2024 | thepharmaletter.comTNewron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian TerritoriesDecember 13, 2024 | finance.yahoo.comEisai unit hands over $46M for Japanese rights to Newron’s schizophrenia add-onDecember 13, 2024 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWPHF, MBIO, NCNA, ARAV, and CYAD Company DescriptionsAravive NASDAQ:ARAV$0.04 0.00 (0.00%) As of 07/9/2025Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Celyad NASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Mustang Bio NASDAQ:MBIO$2.65 -0.03 (-1.12%) Closing price 04:00 PM EasternExtended Trading$2.67 +0.02 (+0.75%) As of 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.NuCana NASDAQ:NCNA$0.05 -0.01 (-15.91%) Closing price 04:00 PM EasternExtended Trading$0.05 +0.00 (+2.59%) As of 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 07/8/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Chipotle: Too Spicy for Smart Money to Resist After Stock Split Plug Power’s 20% Surge Signals New Commercial Growth Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
